✦ LIBER ✦

IV Cefuroxime Plus Oral Clarithromycin or IV Erythromycin for the Treatment of Community-Acquired Pneumonia in Hospitalised Patients

✍ Scribed by Dr Mark H. Gotfried, Aaron D. Killian, Ronald J. Servi, Larry H. Danziger, Keith A. Rodvold

Book ID: 119929200
Publisher: Springer International Publishing AG
Year: 1997
Tongue: English
Weight: 181 KB
Volume: 14
Category: Article
ISSN: 1179-1918
DOI: 10.2165/00044011-199714010-00004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

ClarithromycinvsCombined Cefuroxime and

ClarithromycinvsCombined Cefuroxime and Erythromycin in the Treatment of Hospitalised Community-Acquired Pneumonia Patients — Intravenous Followed by Oral Therapy

✍ N. Vetter, D. Stamler, S. O’Neill, P. Rafferty, G. Praz, J. Duran Cantolla, M. P 📂 Article 📅 1997 🏛 Springer International Publishing AG 🌐 English ⚖ 971 KB

Clinical and bacteriological outcomes in

Clinical and bacteriological outcomes in hospitalised patients with community-acquired pneumonia treated with azithromycin plus ceftriaxone, or ceftriaxone plus clarithromycin or erythromycin: a prospective, randomised, multicentre study

✍ M. Tamm; T. Todisco; C. Feldman; J. Garbino; F. Blasi; P. Hogan; P. J. De Caprar 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 552 KB

Oral Trovafloxacin Compared with Amoxici

Oral Trovafloxacin Compared with Amoxicillin (plus Optional Erythromycin) for the Treatment of Mild to Moderate Community-Acquired Pneumonia

✍ Dr R. Daniel 📂 Article 📅 1999 🏛 Springer International Publishing AG 🌐 English ⚖ 150 KB

Levofloxacin 750-mg for 5 days for the t

Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients

✍ Andrew F. Shorr; Mohammed M. Khashab; Jim X. Xiang; Alan M. Tennenberg; James B. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 125 KB

Cost-effectiveness of oral gemifloxacin

Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia

✍ Sujata M. Bhavnani; Paul G. Ambrose 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 142 KB

AR3 MOXIFLOXACIN IV/PO MONOTHERAPY IS CO

AR3 MOXIFLOXACIN IV/PO MONOTHERAPY IS COST-EFFECTIVE TO THE GERMAN AND FRENCH HEALTHCARE SYSTEMS WHEN COMPARED TO IV/PO AMOXICILLIN/CLAVULANATE ± CLARITHROMYCIN IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA

✍ M Drummond; D Becker; M Hux; J Chancellor; I Duprat-Lomon; PP Sagnier 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB